Canaccord Genuity Maintains Buy on CervoMed, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on CervoMed (NASDAQ:CRVO) with a $65 price target.
July 25, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on CervoMed (NASDAQ:CRVO) with a $65 price target.
The reaffirmation of a Buy rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100